ArticleCell biology and toxicology2026
Meis1-driven suppression of MIF/CD74 signaling promotes M2 macrophage polarization and protects against inflammatory damage in experimental acute lung injury.
Article in Cell biology and toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Acute lung injury (ALI) is marked by dysregulated inflammatory responses, disruption of the alveolar-capillary barrier, and defective tissue repair, in which macrophages function both as drivers of tissue damage and facilitators of resolution. Here, we explored the transcriptional regulation of macrophage polarization in ALI using integrative single-cell and bulk RNA sequencing approaches. Meis1 was identified as a critical transcriptional factor that promotes macrophage skewing toward the M2 phenotype, associated with anti-inflammatory and reparative functions. Mechanistic dissection revealed that Meis1 negatively regulates the MIF/CD74 signaling pathway, thereby limiting pro-inflammatory macrophage activity. Experimental validation in vitro confirmed that Meis1 enhances expression of M2-associated markers while suppressing inflammatory cytokine release. In vivo studies using a murine ALI model demonstrated that Meis1 overexpression alleviates lung inflammation, reduces tissue damage, and accelerates structural repair. These findings establish Meis1 as a key modulator of immune cell fate in injured lungs. Through inhibition of MIF/CD74 signaling, Meis1 constrains inflammatory toxicity and supports tissue repair, revealing a novel regulatory pathway that may be exploited for treating ALI and related inflammatory lung conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.